Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 8.80B P/E 28.86 EPS this Y 117.50% Ern Qtrly Grth 179.00%
Income 59.31M Forward P/E 20.61 EPS next Y 42.50% 50D Avg Chg 9.00%
Sales 6.59B PEG 0.20 EPS past 5Y -20.29% 200D Avg Chg 21.00%
Dividend N/A Price/Book 2.34 EPS next 5Y 35.10% 52W High Chg -8.00%
Recommedations 2.50 Quick Ratio 0.63 Shares Outstanding 679.09M 52W Low Chg 77.00%
Insider Own - ROA 2.14% Shares Float 546.36M Beta 0.67
Inst Own 49.71% ROE 2.20% Shares Shorted/Prior 8.19M/7.10M Price 10.10
Gross Margin 37.84% Profit Margin 0.90% Avg. Volume 842,012 Target Price 15.71
Oper. Margin 12.78% Earnings Date - Volume 1,681,821 Change -1.56%
About Grifols, S.A.

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Grifols, S.A. News
03/22/24 Grifols Drops as Regulator Finds ‘Relevant Deficiencies’
03/08/24 Health Care Roundup: Market Talk
03/08/24 UPDATE 2-Europe's STOXX 600 logs weekly gains, US jobs data in focus
03/06/24 Spanish Healthcare Firm Grifols Hit With New Gotham City's Short Report, Faces Questions Regarding Transparency, Integrity, Ethical Conduct
02:04 PM Grifols Drops 35% as Management Flags Risk of Zero Cash Flow
02/14/24 GRFS or ZTS: Which Is the Better Value Stock Right Now?
02/14/24 Grifols announces positive topline phase 3 fibrinogen clinical trial results
02/05/24 Here's Why Grifols (GRFS) Is a Great 'Buy the Bottom' Stock Now
01/26/24 UPDATE 1-Spain's Grifols sues Gotham City fund, JV over damaging report
01/15/24 Here's Why Grifols (GRFS) is Poised for a Turnaround After Losing -31.55% in 4 Weeks
01/14/24 Grifols says Haier Group still OK to buy stake in Shanghai RAAS
01/12/24 Grifols shares suffer worst week on record after short-seller report
01/12/24 GRFS vs. ZTS: Which Stock Is the Better Value Option?
01/11/24 Grifols sees China stake sale going ahead despite Gotham City report
01/10/24 Spain's Grifols to sue short-seller over critical report, shares jump
01/09/24 Factbox-What does the Gotham City report say about Grifols?
01/09/24 Factbox-What is Grifols and why have its shares slumped?
01/09/24 Grifols Stock Tanks, Short Seller Alleges Profit Manipulation, Concerning Financial Health
01/09/24 Spain's Grifols slumps after short-seller accuses healthcare group of fraud
01/09/24 Gotham City accounting queries wipe $3 billion off Grifols value
GRFS Chatroom

User Image SalmanAziz Posted - 2 days ago

$GRFS the chart pattern for the last six months looks like a bungee jumper whose string just snapped.

User Image ZackInvest008 Posted - 3 days ago

$GRFS This thing trades funny

User Image Robino_Fajkou Posted - 4 days ago

$GRFS Again and again the same cycle, falling to 5.8 and rising again to 6.4-6.5

User Image Bigbossmann Posted - 4 days ago

$GRFS shorts will cover over the next couple of weeks and we will get back to $8.

User Image LouisdeFunes Posted - 4 days ago

$GRFS cheap entry price

User Image HayabusaYamabushi Posted - 4 days ago

$GRFS Upper $7s by April opex

User Image RemitTekram Posted - 5 days ago

$GRFS They have revenues around $6B a year and the CNMV report references adjustments in the $15-30M dollar range. Also states what was in Grifols annual reports as investments should have been joint ventures. This will increase their assumed debt some, but I still think it is in the decimal places and NOT MATERIAL to the solvency of the business. You have to go back to Dec 2011 to have a share price that hit below $5.50. They have been growing in the 13 years since that share price. Even if this takes a year or two, it will recover.

User Image RemitTekram Posted - 5 days ago

$GRFS I love nachos.

User Image Columbiaflyer Posted - 6 days ago

$GRFS Lates update to Yesterday news from Dow Jones News Wire: Grifols got a positive outcome from an investigation by Spanish stock-market regulator CNMV into its accounting even if the regulator found areas for improvement, JPMorgan analysts say in a research note. The deficiencies identified by the CNMV, which the Spanish pharmaceutical company said it is committed to addressing, will likely result in higher indebtedness, but this was likely priced in by equity and credit markets, JPM says. "We believe the CNMV investigation had been a significant overhang on Grifols shares, and we see last night's update as overall being reassuring, given significant historical restatements aren't required and there were no negative surprises. Grifols shares fall 8.1%, after rising earlier in the session, and are down nearly 50% since the beginning of 2024. ([email protected])

User Image bensadri Posted - 6 days ago

$GRFS we will be $10 soon . great entry

User Image ZackInvest008 Posted - 6 days ago

$GRFS sounds more like Gotham was correct. https://finance.yahoo.com/news/grifols-financials-no-big-errors-210612425.html

User Image Columbiaflyer Posted - 6 days ago

$GRFS Lates Version of the same news by Dow Jones News Wire : Grifols got a positive outcome from an investigation by Spanish stock-market regulator CNMV into its accounting even if the regulator found areas for improvement, JPMorgan analysts say in a research note. The deficiencies identified by the CNMV, which the Spanish pharmaceutical company said it is committed to addressing, will likely result in higher indebtedness, but this was likely priced in by equity and credit markets, JPM says. "We believe the CNMV investigation had been a significant overhang on Grifols shares, and we see last night's update as overall being reassuring, given significant historical restatements aren't required and there were no negative surprises. Grifols shares fall 8.1%, after rising earlier in the session, and are down nearly 50% since the beginning of 2024.

User Image Bigbossmann Posted - 6 days ago

$GRFS See what I'm talking about?

User Image Bigbossmann Posted - 6 days ago

$GRFS Funds are accumulating. Any rise in the PPS is beaten back down on small sales. That's how you know you're riding the right horse. This is what it stood at right before the hit piece, that was debunked by the CPA and the regulators.

User Image RemitTekram Posted - 6 days ago

$GRFS Buy when everyone else is afraid to.

User Image MadMaverick Posted - 6 days ago

$GRFS $NVFY $OTLK $FRSX

User Image RemitTekram Posted - 6 days ago

$GRFS Has been in business since 1909. It's not going out of business in 2024.

User Image Bigbossmann Posted - 6 days ago

$GRFS Shorties are so screwed today!!

User Image HayabusaYamabushi Posted - 6 days ago

$GRFS Unfortunately, adding the word "major" to that nonchalant headline puts a foot in the FUD door. You may get another chance at a sub $6 entry.

User Image Bigbossmann Posted - 6 days ago

$GRFS I'm calling $7.25 today, minimum!!

User Image Geradin Posted - 6 days ago

⚡MORNING WATCHLIST⚡ $OTLK Above 10.80 🎯 11.25/11.50 🛑 10.50 $GRFS Above 6.20 🎯 6.45/6.65 🛑 5.95 $NVFY Above 3.17 🎯 3.30/3.40 🛑 3.05 $FRSX Above 1.32 🎯 1.40/1.45 🛑 1.24 Note: These are trade ideas based on break-out levels, once they hit entry & start moving up, I would think about raising your stops to protect your profits and protect your downside :). I personally trade these either on the 2 or 3 min chart, waiting for a candle to close over our entry.

User Image MadMaverick Posted - 6 days ago

⚡MORNING WATCHLIST⚡ $OTLK Above 10.80 🎯 11.25/11.50 🛑 10.50 $GRFS Above 6.20 🎯 6.45/6.65 🛑 5.95 $NVFY Above 3.17 🎯 3.30/3.40 🛑 3.05 $FRSX Above 1.32 🎯 1.40/1.45 🛑 1.24 Note: These are trade ideas based on break-out levels, once they hit entry & start moving up, I would think about raising your stops to protect your profits and protect your downside :). I personally trade these either on the 2 or 3 min chart, waiting for a candle to close over our entry.

User Image Windy007 Posted - 6 days ago

$GRFS Just read the entire report from the regulators….lot of detail and long. Their accounting is really sloppy considering they use a Big 4 firm bot mostly lack of disclosures on transactions than material changes to numbers. Bad look how sloppy they are but stock still cheap

User Image Bigbossmann Posted - 6 days ago

$GRFS Nice pullback here. Shorts are trying to set the stage so they can cover. I didn't think I was going to be able to buy in again after yesterday's good news. Looking for $10.

User Image Zhyg Posted - 6 days ago

$GRFS -8% on good news and low volume? dont think it will stay this low for long

User Image RonIsWrong Posted - 1 week ago

$GRFS Spanish regulators find no major errors in Grifols' accounting: report Spanish regulators have reportedly found no significant errors in Grifols’ accounting of its debt, which had been the subject of a highly critical short-seller report back in January. CNMV, the watchdog agency that oversees Spain’s securities markets, said that its investigation into the matter found “no evidence that the financial debt reported by Grifols does not correspond to reality,” Reuters reported Thursday. The agency did state, however, that it had identified “deficiencies in the detail and accuracy of breakdowns and explanatory notes in some years,” Reuters said, quoting the CNMV. Despite the deficiencies, Grifols will not be required to restate its accounts for 2021 and 2022, Reuters added.

User Image RemitTekram Posted - 1 week ago

$GRFS Average cost per share is good!

User Image Columbiaflyer Posted - 1 week ago

$GRFS Today Spain close at ;GRF Grifols €8.43 +0.329 (+4.06%) At close: Mar 21 5:30 PM EDT

User Image Columbiaflyer Posted - 1 week ago

$GRFS Shortes just got squeezed .

User Image VrtcIl Posted - 1 week ago

Momentum continuing in $GRFS and heading for 7. Keep and eye on elevated highs and lows. The trend structure should remain stable, otherwise take some risk off. Price: 6.71 Float: 256.3M Short Float: 2.9 % 💰 Dollar Volume: 350.0K ℹ️ Spain | Drug Manufacturers - General

Analyst Ratings
Deutsche Bank Sell Mar 12, 24
JP Morgan Neutral Dec 5, 23
Deutsche Bank Hold Nov 5, 21
Credit Suisse Outperform Mar 23, 21
HSBC Buy Mar 11, 21
Santander Buy Oct 28, 19
JP Morgan Overweight Jun 27, 19
Berenberg Hold Feb 8, 19
Morgan Stanley Underweight Jan 2, 19